UY35900A - Nueva dosificación y formulación - Google Patents

Nueva dosificación y formulación

Info

Publication number
UY35900A
UY35900A UY0001035900A UY35900A UY35900A UY 35900 A UY35900 A UY 35900A UY 0001035900 A UY0001035900 A UY 0001035900A UY 35900 A UY35900 A UY 35900A UY 35900 A UY35900 A UY 35900A
Authority
UY
Uruguay
Prior art keywords
formulation
new dosage
micrograms
salmeterol
pharmaceutically acceptable
Prior art date
Application number
UY0001035900A
Other languages
English (en)
Inventor
Arlt Matthias
Ivanoff Nathalie Blandine
Vives Blazquez Montserrat
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of UY35900A publication Critical patent/UY35900A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención proporciona una composición farmacéutica en polvo seco para inhalación, que comprende salmeterol o una sal farmacéuticamente aceptable del mismo y propionato de fluticasona en mezcla con un vehículo en polvo seco farmacéuticamente aceptable, que proporciona una dosis medida de salmeterol / propionato de fluticasona equivalente a aproximadamente 16/280 microgramos o a 16/140 microgramos.
UY0001035900A 2013-12-19 2014-12-19 Nueva dosificación y formulación UY35900A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13382533 2013-12-19

Publications (1)

Publication Number Publication Date
UY35900A true UY35900A (es) 2015-07-31

Family

ID=49886823

Family Applications (2)

Application Number Title Priority Date Filing Date
UY0001035900A UY35900A (es) 2013-12-19 2014-12-19 Nueva dosificación y formulación
UY0001035901A UY35901A (es) 2013-12-19 2014-12-19 Nueva dosificación y formulación

Family Applications After (1)

Application Number Title Priority Date Filing Date
UY0001035901A UY35901A (es) 2013-12-19 2014-12-19 Nueva dosificación y formulación

Country Status (4)

Country Link
AR (2) AR098868A1 (es)
TW (2) TW201605432A (es)
UY (2) UY35900A (es)
WO (2) WO2015091287A1 (es)

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT7920688V0 (it) 1979-02-05 1979-02-05 Chiesi Paolo Parma Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore.
DE3274065D1 (de) 1981-07-08 1986-12-11 Draco Ab Powder inhalator
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
FI69963C (fi) 1984-10-04 1986-09-12 Orion Yhtymae Oy Doseringsanordning
DE3927170A1 (de) 1989-08-17 1991-02-21 Boehringer Ingelheim Kg Inhalator
US5270305A (en) * 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
IT1237118B (it) 1989-10-27 1993-05-18 Miat Spa Inalatore multidose per farmaci in polvere.
US5201308A (en) 1990-02-14 1993-04-13 Newhouse Michael T Powder inhaler
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
GB9015522D0 (en) 1990-07-13 1990-08-29 Braithwaite Philip W Inhaler
WO1992003175A1 (en) 1990-08-11 1992-03-05 Fisons Plc Inhalation device
DE4027391A1 (de) 1990-08-30 1992-03-12 Boehringer Ingelheim Kg Treibgasfreies inhalationsgeraet
DE69132850T2 (de) 1990-09-26 2002-05-29 Pharmachemie Bv Wirbelkammer-Pulverinhalator
GB9026025D0 (en) 1990-11-29 1991-01-16 Boehringer Ingelheim Kg Inhalation device
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
DE4239402A1 (de) 1992-11-24 1994-05-26 Bayer Ag Pulverinhalator
WO1994014492A2 (en) 1992-12-18 1994-07-07 Schering Corporation Inhaler for powdered medications
NZ502870A (en) 1995-06-21 2001-06-29 Asta Medica Ag Inhaler for powdered medicaments comprising a visual display device to indicate the discharge status of the inhaler
DE10129703A1 (de) 2001-06-22 2003-01-02 Sofotec Gmbh & Co Kg Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
ITMI20010357U1 (it) 2001-06-28 2002-12-30 Plastiape Spa Dispositivo inalatore
JP2005539046A (ja) * 2002-08-29 2005-12-22 シプラ・リミテッド 特異的な抗コリン作用薬、β−２アゴニスト、および副腎皮質ステロイドを含む、治療薬および組成物
GB0410712D0 (en) 2004-05-13 2004-06-16 Novartis Ag Organic compounds
DE602005023690D1 (de) 2004-07-16 2010-11-04 Almirall Sa Inhalator für die Abgabe von pharmzeutischen Pulver, und ein Pulverkassette zur Verwendung mit diesem Inhalator
TR201000681A2 (tr) * 2010-01-29 2011-08-22 B�Lg�� Mahmut İnhalasyon yoluyla alınan kuru toz formülasyonları.
EP2571486A4 (en) * 2010-05-20 2013-12-04 Sun Pharma Advanced Res Co Ltd DRY POWDER INHALATION COMPOSITION

Also Published As

Publication number Publication date
AR098868A1 (es) 2016-06-22
WO2015091287A1 (en) 2015-06-25
UY35901A (es) 2015-07-31
TW201609201A (zh) 2016-03-16
AR098867A1 (es) 2016-06-22
WO2015091285A1 (en) 2015-06-25
TW201605432A (zh) 2016-02-16

Similar Documents

Publication Publication Date Title
DOP2016000175A (es) (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
CL2015002733A1 (es) Composición farmacéutica de clorhidrato de s-cetamina.
CY1120684T1 (el) Σκευασμα ξηρης σκονης που περιλαμβανει ενα κορτικοστεροειδες και ενα βητα-αδρενεργικο για χορηγηση δια εισπνοης
DOP2014000269A (es) Nueva dosificación y formulación
CR20140540A (es) Nueva forma de dosificación y formulación de abediterol
BR112015027017A2 (pt) composições farmacêuticas inaláveis e dispositivos inaladores que contêm as mesmas
CL2013003497A1 (es) Producto farmacéutico de combinación en forma de polvo seco para administración por medio de un inhalador que comprende una sal de umeclidinio de un grupo definido y 100 mcg/dosis de furoato de fluticasona, sin otros activos adicionales; uso para el tratamiento de enfermedades inflamatorias o del aparato respiratorio.
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
DOP2015000005A (es) Derivados de estra 1,3,5(10), 16 tetraeno 3 sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
TR201008226A2 (tr) Kapsül içeren bir inhalasyon cihazı.
AR100368A1 (es) Tratamiento de trastornos respiratorios
CL2016001843A1 (es) Uso de una composición que comprende a) un compuesto de fórmula (ia) definida o una sal del mismo y b) un portador o excipiente farmacéuticamente aceptable para preparar un medicamento útil para tratar una afección alérgica en un mamífero.
CL2015002702A1 (es) Composiciones farmacéuticas micronizadas.
UY35900A (es) Nueva dosificación y formulación
ECSP16005208A (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
BR112018006206A2 (pt) composição, uso de uma combinação, forma de dosagem fixa farmacêutica, combinação de dosagem fixa, embalagem, e, uso de uma combinação de dose fixa
TR200907913A2 (tr) İnhalason yolu ile alınmak üzere kuru toz formunda farmasötik bileşim
NI201400138A (es) Nueva dosificación y formulación.
CU20160048A7 (es) Formas de dosificación farmacéutica que comprenden 1-[6-(morfolin-4-il)pirimidin-4-il]-4-(1h-1,2,3-triazol-1-il)-1h-pirazol-5-olato de sodio
TR201716155A1 (tr) Bir beta-2 agonisti ile birlikte bir kortikosteroid içeren farmasötik formülasyon.
TR201716207A2 (tr) Vilanterol ve umeklidinyum içeren farmasötik formülasyonlar.
CO2018005367A2 (es) Composición farmacéutica que contiene, como ingrediente activo, derivado de 7-azaindolin-2-ona o sal farmacéuticamente aceptable del mismo campo técnico
TR201714725A1 (tr) Beta-2 agoni̇sti̇ ve anti̇koli̇nerji̇k i̇çeren kuru toz formülasyonu
TR200907915A2 (tr) Kuru toz formunda farmasötik bileşim.
TR201000730A2 (tr) Tiotropyum ve mometazon içeren kuru toz formundaki farmasötik kompozisyon.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211230